AUGMENTATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NEUTRALIZING ANTIBODY BY PRIMING WITH GP160 RECOMBINANT VACCINIA AND BOOSTING WITH RGP160 IN VACCINIA-NAIVE ADULTS
AUGMENTATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 NEUTRALIZING ANTIBODY BY PRIMING WITH GP160 RECOMBINANT VACCINIA AND BOOSTING WITH RGP160 IN VACCINIA-NAIVE ADULTS
复制标题
DOI：
10.1093/infdis/167.3.533
复制
发表时间：
1993-03-01
影响因子：
6.4
通讯作者：
KOFF, WC
中科院分区：
文献类型：
--
作者：
GRAHAM, BS;MATTHEWS, TJ;KOFF, WC
12 名未接种痘苗的志愿者接种了表达人类免疫缺陷病毒 1 型 (HIV-1) IIIB 株 (HIV-1IIIB) 包膜糖蛋白 gp160 的重组痘苗病毒，随后用 640 杯杆状病毒产生的重组 (r) gp160 蛋白进行免疫。 rgp160加强免疫后，通过Western blot和ELISA检测，所有疫苗接种者的血清均显示出强烈的抗体反应； 8个对同源株具有中和活性，5个对同源株具有融合抑制活性； 5 阻断 CD4 细胞与 gp120 的结合。在中和 HIV-1IIIB 的 8 份血清中，有 3 份检测到 HIV-1MN 的交叉反应中和。活重组牛痘随后进行亚单位加强免疫的组合比单独的任一产品更具免疫原性，并且代表了用于HIV-1免疫预防的有前途的方法。在将临床试验扩展到高危人群之前，有必要进一步定义重组牛痘的安全性以及增强对地理上流行的 HIV-1 毒株的免疫反应。
Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB (HIV-1IIIB) envelope glycoprotein gp160 and subsequently immunized with 640 mug of recombinant (r) gp160 protein produced in baculovirus. After booster immunization with rgp160, the sera of all vaccinees showed strong antibody responses detected by Western blot and ELISA; 8 had neutralizing activity and 5 had fusion inhibition activity against the homologous strain; 5 blocked binding of CD4 cells to gp120. Cross-reactive neutralization of HIV-1MN was detected in 3 of 8 sera that neutralized HIV-1IIIB. The combination of live recombinant vaccinia followed by subunit booster immunization was more immunogenic than either product alone and represents a promising approach for HIV-I immunoprophylaxis. Further definition of recombinant vaccinia safety and augmentation of immune responses to geographically prevalent HIV-1 strains will be necessary before expanding clinical trials to high-risk groups.